Who is sponsoring NCT01681433?

NCT01681433 is sponsored by Costantine Albany.

What condition does NCT01681433 study?

NCT01681433 studies Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, PSA.

What drugs are being tested in NCT01681433?

Interventions: OGX-427, Abiraterone Acetate, Prednisone.

What is the status of NCT01681433?

NCT01681433 is currently TERMINATED.

Last reviewed 2022-07-07 · How we verify

The Pacific Clinical Trial: A Randomized Phase II Study Evaluating OGX-427 in Patients With Metastatic Castrate-Resistant Prostate Cancer (MCRPC)Who Have Prostate-Specific Antigen (PSA) Progression While Receiving Abiraterone: Hoosier Oncology Group GU12-159

NCT01681433 Phase 2 TERMINATED Results posted

This Phase II study has been designed to evaluate the anti-tumor effects of adding OGX-427 to continuing abiraterone acetate and prednisone treatment in men with metastatic castrate-resistant prostate cancer (MCRPC) who have prostate-specific antigen (PSA) progression

Details

Lead sponsor	Costantine Albany
Phase	Phase 2
Status	TERMINATED
Enrolment	72
Start date	2012-12
Completion	2017-06-21

Conditions

Prostate Cancer
Metastatic Castrate-Resistant Prostate Cancer
PSA

Interventions

OGX-427
Abiraterone Acetate
Prednisone

Primary outcomes

Progression-Free Survival — 60 days
To ascertain whether Arm A has a greater proportion of patients observed to be alive without progression at Day 60 (±7 days) as compared to Arm B.

Countries

United States, Canada